Get the Stockscreener App
13.49
1.97%
0.26
Maze Therapeutics Inc stock is traded at $13.49, with a volume of 263.96K.
It is up +1.97% in the last 24 hours and down -20.37% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$13.23
Open:
$13.33
24h Volume:
263.96K
Relative Volume:
2.14
Market Cap:
$591.55M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.07%
1M Performance:
-20.37%
6M Performance:
+11.58%
1Y Performance:
+0.00%
1-Day Range:
$13.30
$14.02
1-Week Range:
$12.81
$14.02
52-Week Range:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
13.49 | 584.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15) - MSN
Analysts Apply Wyckoff Model to Maze Therapeutics Inc. StockTrend Reversal & Accurate Intraday Trading Signals - beatles.ru
Trend Reversal Possible in Maze Therapeutics Inc. Charts Indicate2025 Top Gainers & AI Enhanced Trading Signals - thegnnews.com
Is Maze Therapeutics Inc. a candidate for recovery play2025 Market Outlook & Momentum Based Trading Signals - Newser
Risk adjusted return profile for Maze Therapeutics Inc. analyzedJuly 2025 Spike Watch & Daily Chart Pattern Signal Reports - Newser
Using data models to predict Maze Therapeutics Inc. stock movementJuly 2025 Intraday Action & Short-Term Trading Alerts - Newser
Is it time to cut losses on Maze Therapeutics Inc.July 2025 EndofMonth & High Accuracy Swing Entry Alerts - Newser
Using data filters to optimize entry into Maze Therapeutics Inc.Weekly Risk Summary & AI Enhanced Trading Signals - Newser
Can Maze Therapeutics Inc. hit a new high this monthJobs Report & AI Forecast Swing Trade Picks - Newser
Maze Therapeutics Inc. stock chart pattern explained2025 Investor Takeaways & Long-Term Growth Portfolio Plans - Newser
When is the best time to exit Maze Therapeutics Inc.Trade Volume Report & Daily Market Momentum Tracking - Newser
Using fundamentals and technicals on Maze Therapeutics Inc.July 2025 Decliners & Momentum Based Trading Signals - Newser
Using Ichimoku Cloud for Maze Therapeutics Inc. technicalsLong Setup & Accurate Technical Buy Alerts - Newser
Published on: 2025-08-19 02:45:04 - Newser
Should you wait for a breakout in Maze Therapeutics Inc.Quarterly Risk Review & Expert Verified Movement Alerts - Newser
Maze Therapeutics Inc. Included in Top Momentum Scan2025 Dividend Review & High Return Trade Opportunity Guides - kangso.co.kr
Q3 EPS Forecast for Maze Therapeutics Lowered by Analyst - Defense World
Institutional scanner results for Maze Therapeutics Inc.Weekly Profit Summary & Weekly High Conviction Trade Ideas - Newser
Wedbush Increases Earnings Estimates for Maze Therapeutics - Defense World
Price Reversal in Maze Therapeutics Inc. Traders Watch Closely2025 Top Decliners & Stock Timing and Entry Methods - 선데이타임즈
Published on: 2025-08-16 04:08:13 - Newser
What is Maze Therapeutics Inc.’s book value per shareJuly 2025 Levels & Expert Curated Trade Setup Alerts - sundaytimes.kr
What’s the recovery path for long term holders of Maze Therapeutics Inc.Entry Point & Free Community Consensus Stock Picks - Newser
Visual trend scoring systems applied to Maze Therapeutics Inc.Insider Selling & Community Consensus Trade Alerts - Newser
What moving averages say about Maze Therapeutics Inc.Trade Analysis Summary & Real-Time Buy Signal Notifications - Newser
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Hold at Wall Street Zen - Defense World
HC Wainwright Lifts Earnings Estimates for Maze Therapeutics - Defense World
Will a bounce in Maze Therapeutics Inc. offer an exitBond Market & Fast Gain Swing Trade Alerts - Newser
How Maze Therapeutics Inc. stock performs during market volatility2025 Trading Volume Trends & High Accuracy Trade Signal Alerts - newsyoung.net
Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health - TipRanks
Maze Therapeutics Plunges 17.08% Despite Beating EPS Estimates - AInvest
Why Maze Therapeutics Inc. stock attracts strong analyst attentionPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
RSI Divergence May Trigger a Bounce in Maze Therapeutics Inc.July 2025 Levels & Expert Curated Trade Setups - newsyoung.net
How to escape a deep drawdown in Maze Therapeutics Inc.Weekly Trading Summary & Advanced Swing Trade Entry Alerts - Newser
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials - TipRanks
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782 - TipRanks
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):